Cellibre

• ·Cellibre’s last known valuation is $52.6M (Oct 2024).
• ·It has raised $30.1M across 3 recorded rounds; the latest was Early Stage VC ($6.7M) in Sep 2024.
• ·Notable investors include Alumni Ventures, Liquid 2 Ventures, Prithvi Ventures, Alexander Amand, Arcview Ventures — 20 tracked in total.
• ·1 investment vehicle was formed to buy Cellibre shares in the last 12 months, reporting $55K sold to 8 investors, per SEC Form D filings.
• ·Cellibre has filed 3 Form Ds with the SEC since 2019, most recently Oct 2024 ($6.7M sold to 31 investors).
• ·Status: Privately Held (backing).

In the last 12 months, 1 investment vehicle were formed to buy Cellibre shares, reporting $55K sold to 8 investors. Most recent filing Oct 2025. Vehicles like these are how secondary buyers pool demand for a name; a rising count is a demand signal.

Operator of a cellular agriculture company intended to develop sustainable biological products. The company employs an organism-agnostic approach, precision fermentation, AI-driven enzyme and protein engineering, and high-throughput strain and bioprocess optimization, enabling pharmaceutical, functional health, beauty, and nutraceutical companies to access scalable, lower-cost, higher-quality ingredients while reducing reliance on agriculture and strengthening supply chain resilience.

Sector

Healthcare

HQ

San Diego, CA, United States

Founded

2017

Employees

29

Website

cellibre.com/

Ownership

Privately Held (backing)